Published in Medical Verdicts and Law Weekly, January 18th, 2007
This award is given by the international consultancy to those companies that have stood out in innovation and in implementation of a successful business plan in an increasingly competitive worldwide market.
This award has been presented to Neuropharma due to the R&D that the company is carrying out in the therapeutic area of GSK-3 inhibitors as a new strategy to find an effective treatment for Alzheimer disease. Neuropharma's lead compound from this class, code named as NP-12, is in Phase I clinical trials. NP-12 has so far been administered in 68 subjects, and there have...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.